The clinical results of BCMA targeted therapy were positive

, at the annual meeting of the American Society of Hematology (ASH), Janssen unveiled the latest developments in several projects in its research and development pipeline for the treatment of blood cancers, including the "first-in-class" target for innovative multiple myeloma (MM) target GPRC5D. Dual-specific antibody talquetamab, as well as dual-specific therapy teclistamab targeting B-cell mature antigens (BCMA) and CAR-T therapy Ciltacabtagene Autoleucel (cilta-cel), developed in collaboration with Legendary Biology. Here's a look at the latest developments in these innovative therapies.Talquetamab: Dual-specific antibody GPRC5D, which targets GPRC5D and CD3, is an innovative multiple myeloma target that is highly expressed in multiple myeloma cells and is associated with adverse prognostic factors. Jansen's press release notes that talquetamab is currently the only target in the study of dual-specific antibodies. By combining with CD3 subjects on the surface of T cells, it collects T cells near tumor cells and activates them to attack tumor cells.Phase 1 clinical trial results showed that both intraskinal injections and intravenous injections of talquetamab showed encouraging clinical activity. At the recommended dose in phase 2 clinical trials of subsulpheric injection forms, talquetamab achieved a total remission rate of 69% (9/13), including 39% very good partial remission (VGPR). Of the 9 patients who developed resistance to 3 different pre-treatments, 6 were relieved and 2 patients who developed resistance to 5 different pre-treatments were all relieved. The researchers also found that the use of off-skin injection forms may give patients the opportunity to reduce the frequency of dosage and facilitate treatment.Teclistamab: Dual-specific antibodies BCMA, which targets BCMA and CD3, is a popular target for the treatment of B-cell blood cancer and is highly expressed in multiple myeloma cells. Teclistamab, which collects CD3-positive T cells near multiple myeloma cells expressing BCMA and stimulates cytotoxicity to tumor cells, is currently evaluated in Phase 2 clinical trials to treat patients with relapsed/reassotic multiple myeloma.The latest clinical results published by ASH show that among patients treated with the recommended dose of teclistamab in phase 2 clinical trials of subsulte injection form, ORR reached 73% (16/22), of which 55% achieved very good partial remission (VGPR) and 23% achieved complete remission (CR). At a medium follow-up time of 3.9 months, 95% (15/16) of patients who received remission had no disease progression and the level of remission deepened over time.Cilta-cel: BCMA Target CAR-T Therapy Cilta-cel is a CAR-T therapy that Jansen has developed in combination with Legendary Creatures to target BCMA antigens. Its unique design consists of two antibody protein domains targeting BCMA, eliminating highly expressive multiple myeloma cells by utilizing the killing function of T cells themselves. This CAR-T therapy has been recognized by the FDA as a breakthrough therapy.At ASH's annual meeting, Jansen released the latest results of Cilta-cel in a Phase 1b/2 clinical trial called CARTITUDE-1. Cilta-cel continued to exhibit a very high total remission rate (ORR), reaching 97% at a medium follow-up time of 12.4 months, and over time, the level of patient remission deepened, with 67% of patients achieving strict total remission. At the time of the medium follow-up time of 12.4 months, neither the patient's medium remission duration and progression-free lifetime had been reached.In addition, 93% of patients who could be assessed (n-53) met the criteria for micro-residual lesions (MRD) negative. The progress-free survival rate for 12 months was 77 per cent and the overall survival rate for 12 months was 89 per cent.Patients with multiple myeloma who have developed resistance to three existing therapies often have poor prognosis, but the latest developments announced by Janssen at ash's annual meeting suggest that these patients are expected to welcome innovative therapies to control their condition. (Pharmaceutical Mingkang):. . . Janssen Presents First Data from The Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myomael. Retrieved December 6, 2020, from[2] Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. Retrieved December 6, 2020, from[3] Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma. Retrieved December 6, 2020, from